EVOME MEDICAL TECHNOLOGIES INC. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in CAD from Q1 2021 to Q4 2023

Taxonomy & unit
us-gaap: CAD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Evome Medical Technologies Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2021 to Q4 2023.
  • Evome Medical Technologies Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending December 31, 2023 was CA$7.8M, a 22.8% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (CAD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 7.8M +1.45M +22.8% Dec 31, 2023 10-K 2024-04-16
Q3 2023 9.99M +2.11M +26.8% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 11M +3.75M +51.9% Jun 30, 2023 10-Q 2023-08-14
Q1 2023 7.44M +839K +12.7% Mar 31, 2023 10-Q 2023-05-15
Q4 2022 6.35M +248K +4.07% Dec 31, 2022 10-K 2024-04-16
Q3 2022 7.87M +4.17M +112% Aug 31, 2022 10-Q 2022-10-17
Q2 2022 7.23M +4.09M +130% May 31, 2022 10-Q 2022-07-15
Q1 2022 6.6M +6.6M Feb 28, 2022 10-KT 2023-04-03
Q4 2021 6.1M Dec 31, 2021 10-KT 2023-04-03
Q3 2021 3.71M Aug 31, 2021 10-Q 2021-10-15
Q2 2021 3.14M May 31, 2021 10-Q/A 2021-08-02
Q1 2021 0 Feb 28, 2021 10-K 2022-05-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.